{"disease":{"id":"carcinoma-small-cell-lung","name":"carcinoma small cell lung"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"dacomitnib","indication_name":"Carcinoma, Non-Small-Cell Lung","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"dacomitnib","generic_name":"dacomitnib","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis","quality_score":null,"revenue":null,"mechanism":"patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis"},{"drug_id":"sasanlimab-prefilled-syringe","indication_name":"Carcinoma, Non-Small-Cell Lung","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sasanlimab Prefilled syringe","generic_name":"sasanlimab-prefilled-syringe","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"prefilled syringe","quality_score":0,"revenue":null,"mechanism":"prefilled syringe"},{"drug_id":"sea-tgt","indication_name":"Carcinoma, Non-Small-Cell Lung","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SEA-TGT","generic_name":"sea-tgt","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"solution in vials","quality_score":null,"revenue":null,"mechanism":"solution in vials"}],"offLabel":[],"totalMarketed":0,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT06255197","title":"Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":60000,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT02623712","title":"The Watch the Spot Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":34686,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT05934032","title":"National Network Genomic Medicine Lung Cancer, Germany","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Prof. Dr. Juergen Wolf","has_results":false},{"nct_id":"NCT03517332","title":"Circulating Tumor DNA Exposure in Peripheral Blood","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Quantgene Inc.","has_results":false},{"nct_id":"NCT02194738","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04115410","title":"PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":4724,"lead_sponsor_name":"Sungkyunkwan University","has_results":false},{"nct_id":"NCT02728596","title":"S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)","phase":"NA","overall_status":"COMPLETED","enrollment_count":3665,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT03199651","title":"Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":3584,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03782207","title":"A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2756,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07509333","title":"MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT02475720","title":"Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03232593","title":"A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)","phase":"","overall_status":"COMPLETED","enrollment_count":1758,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02131259","title":"Long-term Observation PMS for Afatinib","phase":"","overall_status":"COMPLETED","enrollment_count":1605,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00324805","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1501,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT00805194","title":"LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1314,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT02285361","title":"GIOTRIF rPMS in Korean Patients With NSCLC","phase":"","overall_status":"COMPLETED","enrollment_count":1272,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04267848","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1210,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02366143","title":"A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1202,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05872763","title":"A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03786003","title":"ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)","phase":"NA","overall_status":"RECRUITING","enrollment_count":1086,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04487080","title":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1074,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT04165798","title":"KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)","phase":"","overall_status":"RECRUITING","enrollment_count":1065,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06160596","title":"Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis","phase":"","overall_status":"RECRUITING","enrollment_count":1020,"lead_sponsor_name":"Cure 51","has_results":false},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT03976323","title":"Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1003,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06494241","title":"Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03918304","title":"Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS","phase":"","overall_status":"COMPLETED","enrollment_count":923,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06131840","title":"A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":914,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT02595944","title":"Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":903,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06769126","title":"Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT07223424","title":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":880,"lead_sponsor_name":"Diwakar Davar","has_results":false},{"nct_id":"NCT04397432","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study","phase":"","overall_status":"UNKNOWN","enrollment_count":878,"lead_sponsor_name":"Tian Xie","has_results":false},{"nct_id":"NCT04380636","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":870,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03976362","title":"A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":851,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07469709","title":"A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","phase":"","overall_status":"RECRUITING","enrollment_count":850,"lead_sponsor_name":"Fondazione del Piemonte per l'Oncologia","has_results":false},{"nct_id":"NCT06868277","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":830,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04794010","title":"A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":825,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02392455","title":"VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)","phase":"","overall_status":"COMPLETED","enrollment_count":817,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06073431","title":"LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT06862869","title":"Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03583528","title":"DOTATOC PET/CT for Imaging NET Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT03872362","title":"Radiomics Multifactorial Biomarker for Pulmonary Nodules","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Maastricht University","has_results":false},{"nct_id":"NCT01523587","title":"LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":795,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}